Royalty Report: Drugs, Cancer, Therapeutic – Collection: 282837

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Disease
  • Proteins
  • Pharmaceuticals
  • Bacterial Infection
  • Assay
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 282837

License Grant
For Exclusive Screening Anticancer Activity,  during the term of this agreement, Licensee shall have the exclusive right to screen Collaboration Compounds for Anticancer Activity.  Until the termination of this agreement,  Licensor, a non-profit cancer treatment and research institution, agrees that  it shall not grant a Third Party the right to screen or develop the Collaboration Compounds, and except in connection with the Research Program, shall not itself screen or develop the Collaboration Compounds for Anticancer Activity.

For the Research License,  Licensor grants an exclusive, with no right to grant sublicenses, under Licensor Patent Rights and Licensor Know-How to make and use methods and materials to carry out the Research Program during the Research Term.

For the Screening License, Licensor grants an exclusive, worldwide license during the term of this agreement to use the Collaboration compounds to conduct screening for anticancer activity.

For the Development and Commercialization License, Licensor grants a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor Patent Rights and Licensor Know-How, to make, use, and develop Collaboration Compounds, and, to make, have made, use, import, offer for sale, sell, and have sold products in the field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
The technology is the discovery and development of Epothilones.

Epothilone shall mean epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, epothilone F, desoxyepothilone F, and any intermediate, derivative, or analog of any of the foregoing compounds.

Product shall mean any pharmaceutical product containing a Collaboration Compound that is selected for development and/or marketing by Licensee or its Affiliates or Sublicensees.

Collaboration Compounds shall mean any Epothilone claimed in Licensor patent rights.

Field of Use
The epothilones are a class of potential cancer drugs. Like taxanes, they prevent cancer cells from dividing by interfering with tubulin, but in early trials epothilones have better efficacy and milder adverse effects than taxanes.

The field shall mean the research, development, manufacture, use, and sale of any Collaboration Compound for any purpose, including but not limited to all human and animal pharmaceutical and agricultural applications.

IPSCIO Record ID: 238988

License Grant
Licensor grants a sole and exclusive license to the Swiss Licensee, with a right to sublicense, under the Licensor Patent Rights and Licensor Know-How to develop, use, sell, offer for sale, import and/or export Compounds and Licensed Products in the Territory and in the Field, and make and have made Compounds and Licensed Products in the Territory for such development, use, sale, offering for sale, importation and/or exportation.
License Property
Licensor owns or possesses certain patent rights, know-how and regulatory filings with respect to epothilones, including epothilone D, and believes that epothilone D has the potential to become an anti-cancer agent.

Compound means any epothilone, or analog, derivative, prodrug or metabolite of an epothilone, including but not limited to epothilone A, B, C and D, a compound that is analog, derivative, prodrug or metabolite of an epothilone, including but not limited to epothilone A, B, C and D, and any compound identified in scientific journals or patent publications as an epothilon, analog, derivative, prodrug or metabolite.

Back-Up Compound means a Compound other than epothilone D that may be suitable for development for use in the Field, until and unless it comes to be included in a Replacement Licensed Product.

Licensed Product means any product containing a Compound, the Commercialization of which would either use Licensor Know-How, including without limitation because the product was researched or developed using Licensor Know-How or but for this Agreement, infringe a Valid Claim.

Field of Use
Field means the treatment, palliation, and/or prevention of cancer.  Potential applications include breast cancer and non-hodgkin lymphoma.

IPSCIO Record ID: 299281

License Grant
University grants a worldwide, exclusive license under the Patent Rights to make and have made, to use and have used, and to offer to sell, sell or import, and have offered to sell, sold or imported, the Licensed Products in the Field of Use, and to practice and have practiced the Licensed Processes and Know-How.

University also grants the right to enter into sublicensing agreements under the Patent Rights.

License Property
The University rights are for the Method for Synthesizing Epothilones and Epothilone Analogs and any other U.S. application owned by the University that has Valid Claims covering the manufacture, use, or sale of [trans-9,10-dehydro-epothilon,D].

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents.

KOS-1584 is our epothilone anticancer clinical candidate that is being evaluated in dose-escalating Phase 1 clinical trials in patients with solid tumors.

Field of Use
The Licensee is developing its epothilone, KOS-1584, in Phase 1 clinical trials and it has shown activity in patients with non-small cell lung, ovarian, breast, pancreatic, prostate and other cancers.

IPSCIO Record ID: 29382

License Grant
Ixabepilone was developed by the Company, but is subject to a License Agreement with a German Licensor, relating to epothilone technologies.
License Property
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog[1] developed as a cancer drug.  Ixempra(ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs.

The Company manufactures its bulk requirements for ixabepilone in its own facilities including the manufacturing of the active ingredient. The drug product which comprises a pharmaceutical kit is finished by Baxter Oncology GmbH.

Field of Use
In October 2007, the FDA approved ixabepilone in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated, and in monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

IPSCIO Record ID: 239020

License Grant
This agreement is between the Licensor, the Licensee and the Institute Licensee which is a division of the Licensee.

For the Research Program, Licensor agrees to conduct the Research Program in collaboration with the Licensee Institute partner with a goal of discovering, identifying and synthesizing Licensed Compounds for Development by Institute Licensee into one or more Products for commercialization by Licensee, an Affiliate or Sublicensee.

During the Exclusive Screening Period, the Institute Licensee shall have the exclusive right to screen Macrolides provided by Licensor for Antibiotic Activity.

During the Non-exclusive screening period, the Institute Licensee and its Affiliates shall have the non-exclusive right to screen the Macrolides, for any biological activity, in any biological test system for any therapeutic indication.

During the Non-exclusive screening period, the Institute Licensee shall have a non-exclusive right to screen the Aromatic Polyketides for any biological activity in any biological test system for any therapeutic indication.

For the Research Licenses to the Institute Licensee, Licensor grants the Institute Licensee a non-exclusive license, with no right to grant sublicenses, under Licensor Patent Rights  and Know-how to make and use methods and materials to carry, out the Research Program during the Research Term.

For the Screening Licenses, Licensor grants to the Institute Licensee the non-transferable licenses, with the right to grant sublicenses to the Institute Licensee Affiliates, under the Licensor Patent Rights and Know-how to conduct screening, an exclusive, worldwide license during the exclusive screening period to use the Macrolides, to conduct screening for Antibiotic Activity;

– a non-exclusive, worldwide license during the non-exclusive screening period (a) to use the Macrolides to conduct screening for Antibiotic Activity; (b) to use the Aromatic Polyketides to conduct screening for any activity; and

– a non-exclusive, worldwide license during the Exclusive Screening Period and Non-exclusive screening period to use the Macrolides to conduct screening for activities other than Antibiotic Activity, excluding any right to screen the Macrolides for Motilide or Anti-inflammatory Activity.

For the Development and Commercialization License Grant, Licensor grants to Licensee a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor patent rights and know-how, to make, use and develop Licensed Compounds, and, to make, have made, use, import, offer for sale, sell and have Sold Products.

License Property
The Licensed Compound shall mean a particular Macrolide or Aromatic Polyketide, as the case may be, with respect to which the Institute Licensee has provided a Designated Notice and acquired an exclusive license. For purposes of this Agreement, each Close Structure Analog of any such Licensed Compound shall also be deemed to be a Licensed Compound.

Macrolides shall mean 14-membered macrolactones, such as erythromycin, their 3-ketolide congeners, 12-membered macrolactones, 15-membered and 16-membered macrolactones, and other macrolactones or ketolide congeners agreed by the Joint Committee, in each case, obtained by expression of genes from, polyketide, synthase gone clusters including, but not limited to, the erythromycin, rapamycin, tylosin, candicidin, picromycin, or oleandomycin] polyketide, synthase gene clusters, in each case, which are actually utilized in connection with the Research Program that exist in Licensors proprietary compound library as of the effective date; or are synthesized or acquired by or on behalf of Licensor or Licensee in connection with the Research Program.

Motilide Activity shall mean motilin receptor agonist or antagonist activity.

Product shall mean any pharmaceutical product containing a Licensed Compound or a Derivative thereof which is selected for Development and/or marketing by Licensee or its Affiliates or Subllicensees.

Field of Use
Field shall mean the treatment of bacterial infections for all human and animal pharmaceutical applications.

IPSCIO Record ID: 319203

License Grant
For the research program, the general goals and intent of the Collaboration are to apply the Exelixis technology to discovering Eligible Targets that may be useful for the discovery and development of small molecule drugs for the prevention, treatment or cure of cancer.

Regarding the Licensor Know-How and Patents.
For Research, Licensor grants a non-exclusive, worldwide, license, under any Licensor Know-How and Patents solely to perform the research tasks assigned and and to perfom research, during the first six months after the end of the Research Term, upon mammalian orthologues of certain Model System Targets.

For Licensee Selected Targets, Licensor grants an exclusive, worldwide license, under any Licensor Know-How and Patents covering the composition, manufacture, or use of one or more Licensee Selected Targets, to make and use each such Licensee Selected Target;
(A) to perform research within the Research Field upon each such BMS Selected Target, including using such Licensee Selected Target to search for Collaboration Compounds,
(B) to develop, and make or have made for use in the Development Field, Licensee Products comprising or incorporating Collaboration Compounds,
(C) to develop, following the commencement of a clinical trial of a Licensee Product in the Development Field, such Licensee Product for any human indication, and
(D) to make, have made, use, import sell offer to sell and have sold Licensee Products.

For Assays, Licensor grants an exclusive, worldwide license, under any Licensor Know-How and Patents covering the composition or use of one or more Assays;
(A) to make and have made such Assay,
(B) to use each such Assay to search for, make and have made
– (1) Collaboration Compounds with activity against the Licensee Selected Target for which such Assay was developed, and
– (2) compounds that lack activity against the Licensee Selected Target for which such Assay was developed,
(C) to develop, and make or have made, for use in the Development Field, and in any defined field licensed by Licensee, Licensee Collaboration Products, and
(D) to develop, following the commencement of a clinical trial of a Licensee Collaboration Product in the Development Field, such Licensee Collaboration Product for any human indication. Such license shall convert to a nonexclusive license, on an Assay-by-Assay basis, on the earlier of the date that is twenty (20) years after the end of the Research Term, or the Licensee Selected Target relating to such Assay becomes an Abandoned Target and is selected by Licensor as a Licensee Selected Target.

For Lead Compounds/Back-Up Compounds, Licensor grants a worldwide, license, under any Licensor Know-How and Patents during the term of this Agreement covering the composition, manufacture, or use of a Lead Compound delivered to Licensee or a Back-up Compound for such Lead Compound;
(A) to make derivatives of such Lead Compounds and Back-up Compounds,
(B) to research, develop, and make or have made for use in the Development Field, Licensor Collaboration Products comprising or incorporating such a Lead Compound or Back-up Compound or derivative thereof,
(C) to develop, following commencement of a clinical trial of such a Licensor Collaboration Product in the Development Field, such Licensee Collaboration Product for any human indication, and
(D) to make, have made, use, import, sell, offer to sell and have sold such Licensee Collaboration Products.

For Pharmacogenomic Uses, Licensor grants a nonexclusive, worldwide license, under the Licensor Know-How and Patents covering the composition, manufacture or use of any Selected Target of either Party, to use such Selected Target in the research, development, manufacture, use, import, sale and offer for sale of a Pharmacogenomic Product for use
(A) in connection with the research, development, manufacture, use, import, sale and offer for sale, for any indication, of a Licensee Product or a product that modulates the same Selected Target as such Licensee product via substantially the same molecular mechanism of action (a Target Product), and
(B) in the labeling, promotion, and registration of any Licensee Product or Target Product for any indication.

For Negative Screening Using Licensor Targets, Licensor grants a non-exclusive, worldwide, bearing license under any Licensee Patents and Know-How covering the
composition, manufacture, or use of an Licensor Selected Target, to use such Licensor Selected Target solely in secondary screening assays developed by or for Licensee to identify, research and develop Collaboration Compounds and Licensee Products that lack the ability to inhibit, activate or otherwise modulate the activity of such Licensee Selected Target.

Foe Licensor Validation Protocols and Reagents, Licensor grants a non-exclusive, worldwide license under the Licensor Know-How and Patents relating to;
(A) the Licensor validation protocols and reagents listed and
(B) all validation protocols and reagents that are developed by Licensor in the course of performing its duties under the Research Plan, to use same for all purposes.

For Improvements to Licensee Validation Protocols and Reagents, Licensor grants a non-exclusive, worldwide license under the Licensor Know-How and Patents to use for all purposes, all improvements to the validation protocols and reagents licensed by Licensee that incorporate or contain any of such validation protocols and reagents licensed by Licensee.

Regarding Target Inventions
– Licensor grants an exclusive, worldwide license, under the Target Inventions invented solely by Licensee and all Patents Controlled by Licensor that claim such Target Inventions, to use such Target Inventions for all purposes other than those for which
Licensor has exclusive rights.

– Licensor grants a worldwide license, under the Target Inventions invented jointly by the Parties and all Patents Controlled by Licensor that claim such Target Inventions, to use, without any accounting or obligation to, or consent required of Licensor, such Target Inventions for all purposes other than those for which Licensor has exclusive rights. The foregoing license is exclusive, with respect to Licensee Selected Targets, for those purposes for which Licensee has exclusive rights; such license is co-exclusive for all other permitted purposes.

License Property
Licensor is a multinational biotechnology company that has expertise and proprietary
technology relating to genetic model systems, functional genomics and computational biology and is applying such technology to discover and validate targets for drug discovery in a variety of disease areas.

Collaboration Compound means any molecule that
(a) has a molecular weight less than or equal to one thousand (1,000) daltons,
(b) is known, prior to the initiation of the first clinical trial for a Product containing such molecule, to have the ability to directly inhibit, activate or otherwise modulate the activity of a Selected Target, or inhibit, activate or otherwise modulate the activity of a Selected Target or its encoded protein in an assay measuring the activity of such Selected Target, and
(c) such ability is identified by or on behalf of a Party or its Affiliate or sublicensee, after the selection of a Selected Target by such Party, through the use to any material extent of such Selected Target or any Information relating to such Selected Target.

DPI Orthologue means a human orthologue.

Eligible Target means a human gene that is
(a) a human orthologue of a Model System Target,
(b) identified prior to the Research Term and during the Research Term or, after the end of the Research Term;
(c) not subject to any previously granted, prior to the identification of such gene as a human orthologue of a Model System Target, and currently in effect license from
Licensor to a Third Party for such Third Party to use such gene or its encoded protein for research in the Research Field or development, in the Development Field, of a small molecule product directed at such gene or its encoded protein or to make, use, import, offer for sale or sell such a product; provided, that so long as such license is not exclusive, the Licensee members of the JSC may elect to waive the requirements under this subsection (c) as to any given gene, and
(d) either not claimed in an issued Third Party patent covering its composition of matter or method of use in oncology,

Model System Target means an invertebrate or non-human, vertebrate gene.

Phenotypic Screen means a screen performed in a wild-type cell or organism in which certain genes are turned on or off and the effect thereof is measured through the use of an assay that measures a biological response in the Research Field.

Field of Use
Research Field means cancer research regarding
(a) growth regulation,
(b) cell cycle control,
(c) DNA damage response,
(d) cell survival,
(e) cell adhesion, or
(f) apoptosis as they pertain to cancer, as well as the adenomatous polypossis coli gene (apc} For clarity, the Research Field does not include angiogenesis/lymphangiogenesis research or research regarding cell motility or cell-cell communication (it being understood that cell-cell communication does not encompass cell adhesion which shall be included within the Research Field.

Development Field means the treatment or prophylaxis of any type of human cancer.

The Parties are establishing a collaboration to apply such Licensor technology and expertise to the identification and characterization of biochemical pathways and targets in specific research areas relevant to cell growth and proliferation, to generate small molecule therapeutic or prophylactic compounds directed against such targets, and to provide for the development and commercialization of novel therapeutic and prophylactic products based on such research.  In a cooperative effort that will leverage each Licensees technology and expertise in the fields of genomics and target validation, Licensor will identify and validate molecular targets that trigger cell death in cancer cells, while leaving normal cells unharmed. Licensee will then further validate these targets in human models.

IPSCIO Record ID: 289168

License Grant
The Parties will collaborate in the discovery, development and commercialization of products for use in the prevention, and/or treatment of certain human diseases.

Licensor grants Licensee under the Licensor Patents, Licensor Know-How and Licensors interest in the Research Technology and the Research Technology Patent Rights
— a non-exclusive, worldwide, right and license, without the right to sub license, solely to conduct its Research activities pursuant to this Agreement during the Research Term; and
— if Licensee exercises its License Option, commencing at the expiration of the Research Term and for a period of 3 years thereafter, a non-exclusive, worldwide,  right and license, with the right to sub license solely to optimize, and, in connection with Licensees activities under this Agreement, make and use, but not sell, offer for sale or import, solely in connection with such optimization, Released Compounds for use in the Field.

Licensor grants Licensee an exclusive option during, the 4 month period following each decision by Licensor not to advance any particular Candidate Compound as either a Clinical Development Compound or Back-Up Compound, to obtain an exclusive, including with regard to Licensor, world-wide, right and license, with the right to sublicense, under the Licensor Patents and Licensor Know-How solely to conduct development on, and to make, have made and use for such purpose, any such Released Compounds for use in the Field, and to make, have made, import, use, sell and offer for sale pharmaceutical products containing or comprising any such Released Compounds in any formulation, each, a Released Product, for use in the Field.

License Property
Licensor is engaged in the research, development and marketing of products for the treatment of, among other things, diseases within the field of cancer.

Licensed Product means any product, including any formulation thereof, containing or comprising a Clinical Development Compound for use within the Field.

Licensor will initially provide Licensee with approximately [0.5 micromoles] each of approximately four hundred thousand (400,000) compounds, each an Licensor Compound in a 384 well format.

Field of Use
Field means any and all uses for the prevention or treatment of human disease. Licensee and its Affiliates possess proprietary technology and know-how related to modulation of caspases.

Caspases are a family of protease enzymes playing essential roles in programmed cell death.

IPSCIO Record ID: 222558

License Grant
For the Compounds and Products, Licensor grants an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology, exclusive even as to Licensor and its Affiliates, to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to  Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each  grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows  the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.

For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.

License Property
Licensor has developed proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.  'Licensor Technology' shall mean Existing Licensor Patent Rights, Existing Licensor Know-How, and Licensor Improvements (with some exceptions).

Product means any Agreement Product or Licensees Product.

Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.

Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.

Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.

Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'

Field of Use
This agreement field relates to assays, compound screening methods and biological research tools used to design, prepare and screen compound libraries against Licensees biological targets.

IPSCIO Record ID: 289543

License Grant
The Parties are collaborating in the discovery, development and commercialization of products for use in the prevention, and/or treatment of certain human diseases as identified below.

Licensor grants under the Licensor Patents,  Licensor Know How and Licensors interest in the Research Technology and Research Technology Patent Rights
—  a non-exclusive, worldwide right and license solely to conduct its Research activities pursuant to this Agreement during the Research Term.
—  Commencing at the expiration of the Research Term and for a period of three years thereafter, a non-exclusive, worldwide right and license to optimize and, in connection with Axys activities under this Agreement, make and use, but not sell, offer for sale or import, Candidate Compounds for use in the Field subject to all other provisions of this Agreement relating to Licensed Products.

License Property
Licensor possess proprietary technology and know-how related to modulation of caspases.

Licensor will initially contribute to the Research, from its libraries of compounds, two 2 compounds – each, a Licensor Compound, identified by the Parties which will be the subject of initial research related activities as provided in the Research Plan.

Apoptosis, or programmed cell death, is a necessary and normal function used by the body to remove damaged cells in an orderly way. Apoptosis is mediated by caspases, a cascade of interconnected enzymes inside the cell, which are normally dormant, but become activated under certain stimuli.

Field of Use
The Parties have entered into a collaboration to discover and develop anti-cancer agents that induce apoptosis (programmed cell death).

IPSCIO Record ID: 237218

License Grant
For the Mutual Research Licenses, the Licensor of Sweden grants, during the term of the Research Program, a co-exclusive, solely with Licensor, world-wide right and license under the Licensor Licensed Technology and Licensor Collaboration Technology, and a co-exclusive, solely with Licensor, world-wide right and sublicense under the ASU Licensed Technology, to conduct the Research Program and to make and use Collaboration Compounds and Covered Products in connection with the Research Program, each in accordance with the terms of this Agreement.

For the Licensee Commercialization License, Limited Partial Conversion to Non-exclusivity, subject to Licensors limited right to manufacture Collaboration Compounds and Covered Products, Licensor grants an exclusive, even as to Licensor, world-wide, royalty-bearing right and sublicense in the Field throughout the Territory, with the right to grant further sublicenses in accordance with the terms of this Agreement, under the ASU Licensed Technology to develop, make, have made, use, sell, offer for sale, have sold and export Covered Products.

Licensor grants an exclusive, even as to Licensor, world-wide right and license in the Field throughout the Territory, with the right to grant sublicenses in accordance with the terms of this Agreement, under the Licensor Licensed Technology, the Licensor Collaboration Technology and Licensors interest in the Joint Collaboration Technology to develop, make, have made, use, sell, offer for sale, have sold and export Covered Products.

For the Mutual Ex-Field Licenses, Licensor grants a perpetual, non-exclusive, world-wide right and license, with the right to grant sublicenses, under the Licensor Collaboration Technology and Joint Collaboration Technology for all purposes outside the Field.

License Property
Licensor has been granted a license, with the right to sublicense, certain patent rights and other know-how and technology owned by Arizona State University.

Collaboration Compound shall mean any chemical compound, the composition of matter and/or method of use of which is, or is deemed to be, covered by the ASU Licensed Technology, the Licensor Licensed Technology and/or the OXiGENE Collaboration Technology, and that is the subject of any of the research, development, commercialization and/or marketing activities contemplated by this Agreement. While the Parties intend CA4P to be the initial Collaboration Compound, other compounds may be selected as Collaboration Compounds in addition to, or in lieu of, CA4P.

Combretastatin shall mean any cancer cell growth inhibitory substance derived from the bush willow Combretum caffrum.

CA4P shall mean the chemical compound having the chemical name Combretastatin A4 phosphate.

Field of Use
Field shall mean the prevention, diagnosis, control or treatment of any human or animal disease or condition by the Systemic Use of a Covered Product(s), either as a single agent or in combination with any other therapy. The Field may be modified from time to time.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.